Articles published in Health Economics & Outcome Research: Open Access have been cited by esteemed scholars and scientists all around the world. Health Economics & Outcome Research: Open Access has got h-index 10, which means every article in Health Economics & Outcome Research: Open Access has got 10 average citations.
Following are the list of articles that have cited the articles published in Health Economics & Outcome Research: Open Access.
| 2022 | 2021 | 2020 | 2019 | 2018 | |
|---|---|---|---|---|---|
Year wise published articles |
56 | 59 | 13 | 14 | 15 |
Year wise citations received |
53 | 46 | 45 | 39 | 18 |
| Journal total citations count | 281 |
| Journal Impact Factor | 0.87 |
| Journal 5 years Impact Factor | 1.29 |
| Journal CiteScore | 1.30 |
| Journal h-index | 10 |
| Journal Impact Factor 2020 formula |
| IF= Citations(y)/{Publications(y-1)+ Publications(y-2)} Y= Year |
| Journal 5-year Impact Factor 2020 formula |
| Citations(2016 + 2017 + 2018 + 2019 + 2020)/ {Published articles(2016 + 2017 + 2018 + 2019 + 2020)} |
| Journal CiteScore |
| CiteScorey = Citationsy + Citationsy-1 + Citationsy-2 + Citations y-3 / Published articlesy + Published articlesy-1 + Published articlesy-2 + Published articles y-3 |
Ludmir J, Small AJ, Bui MP. The challenge of identifying and addressing psychological comorbidities. |
|
Desan PH, Lee HB, Zimbrean P, Sledge W. New models of psychiatric consultation in the general medical hospital: liaison psychiatry is back. Psychiatric Annals. 2017 Jul 1;47(7):355-61. |
|
Oldham MA, Chahal K, Lee HB. A systematic review of proactive psychiatric consultation on hospital length of stay. General hospital psychiatry. 2019 Sep 1;60:120-6. |
|
Bays AD. Relationship Between Hospital Performance and Medicare Reimbursement Penalties (Doctoral dissertation, Walden University). |
|
Soto Ruiz de Gordoa M. Healthcare costs of breast, prostate, colorectal and lung cancer care by clinical stage and cost component= Costes de la atención de los cánceres de mama, próstata, colorrectal y pulmón por estadio clínico y componente de coste. |
|
de la Haba Rodriguez J, Fernandez P, Rodriguez-Lescure A, CA RS, Ruiz-Borrego M, Remak E, Barra M, Rivero M. The economic burden of metastatic breast cancer in Spain. European Journal of Hospital Pharmacy: Science and Practice. 2018 Jul 30;27(1):19-24. |
|
Myrzamatova AO, Kontsevaya AV, Gorny BE, Drapkina OM. Population prevention measures aimed at reducing alcohol consumption: international experience and prospects for strengthening measures in the Russian Federation. Cardiovascular therapy and prevention. 2020; 19 (3). |
|
Rezapour A, Nargesi S, Mezginejad F, KEMMAK AR, Bagherzadeh R. The economic burden of cancer in iran during 1995-2019: A systematic review. Iranian Journal of Public Health. 2021;50(1):35-45. |
|
de Las Heras BB, y Cajal JC, Calvo EG, de la Haba Rodriguez J, Mata JG, Anton FM, Fernandez IP, Rodriguez-Lescure A, Sanchez CA, Ruiz-Borrego M, Remak E. The economic burden of metastatic breast cancer in Spain. European Journal of Hospital Pharmacy. 2020 Jan 1;27(1):19-24. |
|
Rodriguez-Rincon D, Leach B, D’Angelo C, Harshfield A, Manville C. Factors affecting access to treatment of early breast cancer: Case studies from Brazil, Canada, Italy, Spain and UK. Santa Monica, CA: RAND Corporation. 2019. |
|
Kontsevaya AV, Balanova YA, Myrzamatova AO, Khudyakov MB, Mukaneeva DK, Drapkina OM. Economic losses due to oncologic diseases related to modifiable risk factors. Analiz riska zdorov'yu. 2020(1):133. |
|
Kontsevaya AV, Balanova YA, Myrzamatova AO, Khudyakov MB, Mukaneeva DK, Drapkina OM. Economic damage of oncological diseases associated with modifiable risk factors. Health risk analysis. 2020 (1). |
|
Alonso-García M, Sarría-Santamera A. The economic and social burden of low back pain in Spain: a national assessment of the economic and social impact of low back pain in Spain. spine. 2020 Aug 15;45(16):E1026-32. |
|
Pardo Jimeno J. Departamento de Microbiología, Pediatría, Radiología y Salud Pública. |
|
Pardo Jimeno J. Relevancia de la inflamación mediada por la granzima A en autoinmunidad y cáncer. |
|
Puig L, Ruiz de Morales JG, Dauden E, Andreu JL, Cervera R, Adán A, Marsal S, Escobar C, Hinojosa J, Palau J, Arraiza A. The prevalence of ten immune-mediated inflammatory diseases (IMID) in Spain. Spanish magazine of Public Health. 2019; 93. |
|
Capron JP, De Leonardis F, Fakhouri W, Dilla T, Diaz S, Inciarte J, Burke T. THE IMPACT OF DISEASE DURATION AND DISEASE ACTIVITY ON THE COST OF RHEUMATOID ARTHRITIS IN SPAIN: RESULTS FROM BURDEN OF RHEUMATOID ARTHRITIS ACROSS EUROPE A SOCIOECONOMIC SURVEY (BRASS). |
|
Gil-Conesa M, Del-Moral-Luque JA, Gil-Prieto R, Gil-de-Miguel Á, Mazzuccheli-Esteban R, Rodríguez-Caravaca G. Hospitalization burden and comorbidities of patients with rheumatoid arthritis in Spain during the period 2002–2017. BMC health services research. 2020 Dec;20(1):1-8. |
|
Puig L, Ruiz de Morales JG, Dauden E, Andreu JL, Cervera R, Adán A, Marsal S, Escobar C, Hinojosa J, Palau J, Arraiza A. La prevalencia de diez enfermedades inflamatorias inmunomediadas (IMID) en España. Revista Española de Salud Pública. 2020 Oct 12;93:e201903013. |
|
Schlueter M, Finn E, Díaz S, Dilla T, Inciarte-Mundo J, Fakhouri W. Cost-effectiveness analysis of baricitinib versus adalimumab for the treatment of moderate-to-severe rheumatoid arthritis in Spain. ClinicoEconomics and outcomes research: CEOR. 2019;11:395. |
|
